ALK and lung cancer: Entrectinib received FDA approval for lung cancers harbouring ROS1 alteration in 2019 [46,47,98], having demonstrated robust ALK and ROS1 inhibition, plus effective TRKA, TRKB and TRKC signalling suppression [99].